Palisade Bio Participates in Virtual Investor “What this Means” Segment

Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) has released a Virtual Investor 'What This Means' segment featuring Chief Medical Officer Mitchell Jones, MD, PhD. The segment focuses on the company's recent microbiome study that confirmed bacterial enzymes for local bioactivation of their lead product candidate, PALI-2108. This development is significant for Palisade Bio's planned Phase 1 human clinical study for the treatment of Ulcerative Colitis.

The company, which specializes in developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, views this as an important step forward in their research. The Virtual Investor segment is now available online, providing investors and interested parties with insights into the implications of this study for Palisade Bio's future clinical trials and potential treatment options.

Positive

• Successful completion of microbiome study confirming local bioactivation of lead product PALI-2108
• Progress towards planned Phase 1 human clinical study for Ulcerative Colitis treatment

Negative

• None.

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Carlsbad, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor “What This Means” segment.

As part of this “What this Means” segment, Mitchell Jones, MD, PhD, Chief Medical Officer of Palisade Bio discusses the successful completion of a microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, and what this means for its planned Phase 1 human clinical study for the treatment of Ulcerative Colitis.

The Virtual Investor “What This Means” segment featuring Palisade Bio is now available here. Additional videos from the “What This Means” series are available on demand at www.virtualinvestorco.com.

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com

FAQ

What is the significance of Palisade Bio's recent microbiome study for PALI-2108?

The microbiome study confirmed bacterial enzymes for local bioactivation of PALI-2108, which is significant for Palisade Bio's planned Phase 1 human clinical study in treating Ulcerative Colitis.

What is PALI-2108 being developed to treat?

PALI-2108 is being developed as a potential treatment for Ulcerative Colitis, an inflammatory bowel disease.

When did Palisade Bio (PALI) release the Virtual Investor 'What This Means' segment?

Palisade Bio released the Virtual Investor 'What This Means' segment on July 31, 2024.

Who presented Palisade Bio's (PALI) findings in the Virtual Investor segment?

Mitchell Jones, MD, PhD, Chief Medical Officer of Palisade Bio, presented the findings in the Virtual Investor segment.